Nipro : Notice of Contract Manufacturing Agreement for Domestic Supply of AstraZeneca COVID-19 vaccine “Vaxzevria™ intramuscular injection”

May 26, 2021

NIPRO CORPORATION

Notice of Contract Manufacturing Agreement for Domestic Supply

of AstraZeneca COVID-19 vaccine "Vaxzevria™ intramuscular injection"

Nipro Corporation (Headquarters: Kita-ku, Osaka, Japan; President & Representative Director: Yoshihiko Sano; hereafter, "Nipro") and our pharmaceutical manufacturing subsidiary Nipro Pharma Corporation (Headquarters: Chuo-ku, Osaka, Japan; President & Representative Director: Kenichi Nishida; hereafter, "Nipro Pharma") hereby announces that we have entered into a Contract Manufacturing Agreement (hereafter, "Agreement") with AstraZeneca

1. (Headquarters: Kita-ku, Osaka, Japan; Representative Director and President: Stefan Woxström; hereafter, "AstraZeneca") for the fill and finish process of AstraZeneca's COVID-19 vaccine, "Vaxzevria™ intramuscular injection" (hereafter, "Product").

A Special approval for the emergency use of the Product in Japan was granted to AstraZeneca on 21st May, 2021. More than 90 million doses, among the contracted 120 million doses which AstraZeneca has entered into a supply agreement with the Japanese government, will be manufactured domestically in Japan from manufacturing of drug substance to fill and finish process. Following the execution of this agreement, Nipro Pharma will formulate a portion of its domestic manufacturing capacity from June 2021. The Product can be distributed and stored at refrigerated temperature (2-8°C) for at least six months.

Nipro Pharma will continue to make every effort to manufacture the Product and to maintain and expand the production capacity based on careful technical assistance received from AstraZeneca and the manufacturing facilities and production system built for the production of vaccines.

As a comprehensive medical device and pharmaceutical manufacturer, we will continue to contribute with technology of confidence to achieve reduction in COVID-19.

※Vaxzevria TM is a trademark of AstraZeneca.

Inquiries regarding the content of this release: TEL +81-6-6375-6709,

Pharmaceutical Development Promotion Department, Pharmaceutical Division

※Acceptance hours: 9:00-17:45 (excluding Saturdays, Sundays, holidays, and company holidays)